Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Its recurring updates center on the commercial performance of FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel), along with financial results, revenue guidance, conference presentations, and business updates.
Company news also covers product-specific medical and legal developments, including vamorolone research in Duchenne muscular dystrophy and patent litigation settlements involving FIRDAPSE. Additional announcements address patient advocacy initiatives, support services, and strategic portfolio activity tied to Catalyst’s U.S.-based rare-disease commercial model.
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focusing on rare and difficult-to-treat diseases, has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host a conference call and webcast on August 8, 2024, at 8:30 AM ET to discuss the financial results and provide a business update.
Investors can access the call via US/Canada dial-in number (877) 407-8912 or international dial-in number (201) 689-8059. The webcast will be available under the Investors section on Catalyst's website, with a replay accessible for at least 30 days following the event.
Catalyst Pharmaceuticals has received FDA approval to increase the maximum daily dose of FIRDAPSE® from 80 mg to 100 mg for treating Lambert-Eaton myasthenic syndrome (LEMS) in patients over 45 kg. This adjustment provides more flexibility in treatment options for both adult and pediatric patients. FIRDAPSE, a potassium channel blocker, is the only FDA-approved treatment for LEMS, a rare autoimmune disorder that causes muscle weakness and fatigue. Catalyst's CEO Richard J. Daly highlighted the significance of this approval in enhancing patient outcomes. The Catalyst Pathways® Patient Assistance Program offers additional support for those seeking treatment information.
Catalyst Pharmaceuticals announced its participation in the Jefferies Global Healthcare Conference 2024, scheduled for June 5, 2024, in New York. CEO Richard J. Daly and other management members will represent the company at the event. The presentation will be available via webcast on the Catalyst Pharmaceuticals website and archived for 14 days. Catalyst focuses on in-licensing, developing, and commercializing novel treatments for rare and difficult-to-treat diseases. This event represents an opportunity for Catalyst to showcase its progress and future plans to investors and industry stakeholders.
Catalyst Pharmaceuticals reported solid first-quarter 2024 financial results, achieving total revenues of $98.5 million, a 15.4% YoY increase. Highlights include the successful launch of AGAMREE®, robust revenue momentum for FIRDAPSE®, and reaffirmed full-year 2024 total revenue guidance of $455-475 million.
Catalyst Pharmaceuticals, Inc. will participate in the BofA Securities Health Care Conference 2024. Richard J. Daly, President and CEO, will lead the team at the event in Las Vegas, Nevada. The presentation will take place on May 14, 2024, at 5:00 pm PT. Investors can access the webcast on the company's website with a replay available for at least 14 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.